Imke H Bartelink
Country: The Netherlands
- Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerationsImke H Bartelink
Department of Pharmacy, University Medical Center, Utrecht, The Netherlands
Clin Pharmacokinet 45:1077-97. 2006..The integration of these guidelines, and combining them with pharmacodynamic effects, should be considered and could form a basis for further study...
- Predictive performance of a busulfan pharmacokinetic model in children and young adultsImke H Bartelink
Department of Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands
Ther Drug Monit 34:574-83. 2012....
- Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosingImke H Bartelink
Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
Clin Pharmacokinet 51:331-45. 2012..1 to 26 years of age, elucidate patient characteristics that explain the variability in exposure between patients and optimize dosing accordingly...
- Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantationImke H Bartelink
Department of Hematology, University Medical Center Utrecht, The Netherlands
Biol Blood Marrow Transplant 14:88-98. 2008..TDM was feasible in routine clinical practice. The results show that i.v. Bu using TDM is preferable over oral Bu in children undergoing allogeneic stem cell transplantation, especially in those at high risk for graft failure/relapse...